Skip to NavigationSkip to content

New drug for treatment-resistant HIV approved

Published on 28/06/06 at 01:53pm

Prezista, a new drug for patients who have treatment-resistant HIV, has been approved in the US.

The treatment from Johnson & Johnson is a new protease inhibitor, which will be used in conjunction with 100mg ritonavir and other antiretroviral agents.

"One of the greatest challenges in HIV care is finding therapies for treatment-experienced patients," said Michael Saag, director of the AIDS Outpatient Clinic and the University of Alabama. "This is an important new option for the thousands of people with HIV in the United States who are resistant to more than one protease inhibitor."

Prezista (darunavir ) was developed by Tibotec Pharmaceuticals, which was acquired by J&J in 2002.

The drug was filed in Europe in January, with EMEA approval expected shortly.

Tibotec Pharmaceuticals is based in Cork in Ireland, but the company's main research and development facilities are in Mechelen, Belgium. The company specialises in discovering and developing new drugs in HIV/AIDS, hepatitis and TB.


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches